Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27 2023 - 7:00AM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patients’ lives by
developing and commercializing innovative products across a range
of therapies, today announced that Paul R. Edick, Xeris’ Chairman
and CEO, will present an overview of the Company at the 42nd Annual
J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at
12:00 pm Pacific Time. To access the presentation, please visit
“Events” on the investor relations page of the Company’s website at
www.xerispharma.com.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing innovative products across a range of therapies.
Xeris has three commercially available products; Gvoke®, a
ready-to-use liquid glucagon for the treatment of severe
hypoglycemia, Keveyis®, a proven therapy for primary periodic
paralysis, and Recorlev® for the treatment of endogenous Cushing’s
syndrome. Xeris also has a robust pipeline of development programs
to extend the current marketed products into important new
indications and uses and bring new products forward using its
proprietary formulation technology platforms, XeriSol™ and
XeriJect®, supporting long-term product development and commercial
success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on X,
LinkedIn, or Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231227139846/en/
Allison Wey Senior Vice President, Investor Relations and
Corporate Communications awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jul 2023 to Jul 2024